DermR Health

The DermR Patch is a world-first microneedle device designed to painlessly collect skin cells, offering a new method for screening skin cancer. Our solution replaces traditional biopsies as a first-tier approach with a less invasive, more efficient method, addressing the growing global challenges of inefficient skin cancer diagnosis, where 40% of biopsies are benign and could be avoided. Samples can be posted to any genomic-equipped pathology provider and tested using our proprietary Skin Cancer RNA Assay. Our assay can detect cancerous gene expression changes against the spectrum of skin cancers, including melanoma, using just a few cells, offering a pre-screening solution to identify if a lesion may or may not be cancerous. Moreover, the DermR Patch supports Next-Gen Sequencing for full human genome analysis, opening new avenues for research into hundreds of other diseases. We’re not just advancing skin cancer detection; we’re setting new standards in dermatology and beyond.